Hope for prostate cancer treatment

A new monoclonal antibody drug is showing promise in the treatment of advanced prostate cancer, a European conference will hear today.

Major studies of the drug are about to begin on patients after the success of an early trial involving 50 people.

The early studies found the drug reduced levels of cancer cells circulating in the patients’ bodies.

The drug is designed to bind to a protein called prostate specific membrane antigen – PSMA – on the surface of a cancer cell.

The findings were being reported at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.

Researcher Professor Daniel Petrylak, of Columbia University Medical Center, New York, USA, said the next phase of research would involve some 75 patients.

He said: "These results show that PSMA ADC has anti-tumour activity in patients who have failed up to two prior chemotherapies and hormone therapy.

"The fact that this new targeted therapy is active against the most advanced forms of prostate cancer is encouraging, as few or no therapeutic options are available at present."

Conference chair Professor Stefan Sleijfer, of Erasmus University Medical Centre, The Netherlands, said: "The anti-tumour effects already seen at such an early phase of clinical testing, such as a fall in circulating tumour cells, render this drug a promising compound for prostate cancer."

, , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

Categories

Monthly Posts

Our Clients

BSH
Practice Index